223 related articles for article (PubMed ID: 9219422)
1. PSA excess in the differential diagnosis of prostate carcinoma.
Díaz F; Morell M; Rojo G
Arch Esp Urol; 1997 May; 50(4):415-8. PubMed ID: 9219422
[TBL] [Abstract][Full Text] [Related]
2. [Serum and urine prostate-specific antigen ratio: its value in the distinction between prostate cancer and adenoma when serum prostate-specific antigen level is between 4 and 10 ng/ml].
Irani J; Millet C; Levillain P; Doré B; Bégon F; Aubert J
Chirurgie; 1997; 122(8-9):478-82. PubMed ID: 9616891
[TBL] [Abstract][Full Text] [Related]
3. Free to total prostate-specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer.
Van Cangh PJ; De Nayer P; Sauvage P; Tombal B; Elsen M; Lorge F; Opsomer R; Wese FX
Prostate Suppl; 1996; 7():30-4. PubMed ID: 8950361
[TBL] [Abstract][Full Text] [Related]
4. Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.
Filella X; Truan D; Alcover J; Quintó L; Molina R; Luque P; Coca F; Ballesta AM
Urology; 2004 Jun; 63(6):1100-3; discussion 1103-4. PubMed ID: 15183958
[TBL] [Abstract][Full Text] [Related]
5. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
6. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
Uno H; Koide T; Kuriyama M; Ban Y; Deguchi T; Kawada Y
Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060
[TBL] [Abstract][Full Text] [Related]
7. The value of percent free prostate specific antigen, prostate specific antigen density of the whole prostate and of the transition zone in Turkish men.
Akduman B; Alkibay T; Tuncel A; Bozkirli I
Can J Urol; 2000 Oct; 7(5):1104-9. PubMed ID: 11114873
[TBL] [Abstract][Full Text] [Related]
8. A higher PSA-density cut-off level in patients with intermediate PSA values for the early detection of prostate cancer.
Mochtar CA; Rahardjo D; Umbas R
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():514-22. PubMed ID: 10895203
[TBL] [Abstract][Full Text] [Related]
9. Is there a role for serum human tissue kallikrein in detection of prostate cancer?
Ochiai A; Shukla A; Davis JW; Fritsche HA; Bhadkamkar V; Babaian RJ
Urology; 2007 Sep; 70(3):519-22. PubMed ID: 17905108
[TBL] [Abstract][Full Text] [Related]
10. [Clinical significance of prostate specific antigen (PSA) and PSA density in the detection of T1a and T1b prostate cancer].
Meguro N; Maeda O; Saiki S; Kinouchi T; Kuroda M; Usami M; Kotake T
Hinyokika Kiyo; 1998 Sep; 44(9):639-43. PubMed ID: 9805668
[TBL] [Abstract][Full Text] [Related]
11. Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer.
Romppanen J; Haapalainen T; Punnonen K; Penttilä I
Anticancer Res; 2002; 22(1A):415-20. PubMed ID: 12017325
[TBL] [Abstract][Full Text] [Related]
12. [Determination of tumor markers in the diagnosis of prostatic cancer].
Casas Terrón E; Mari Ruiz M; Molina Andreu E
Arch Esp Urol; 1993 Mar; 46(2):99-103. PubMed ID: 7684585
[TBL] [Abstract][Full Text] [Related]
13. [Does plasmatic dilution influence the validity of PSA-tests?].
Rohde D; Mihelcic V
Aktuelle Urol; 2007 Mar; 38(2):137-43. PubMed ID: 17390276
[TBL] [Abstract][Full Text] [Related]
14. [The quotient of prostate-specific antigen and prostate volume. Improved differentiation between benign prostatic hyperplasia and locally circumscribed prostate cancer].
Semjonow A; Hamm M; Rathert P
Urologe A; 1993 May; 32(3):250-3. PubMed ID: 7685557
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of serum prostate specific antigen as a tumour marker in prostatic carcinoma: a comparison with serum acid phosphatase.
Cooke RR; Nacey JN; Beeston RE; Delahunt B
N Z Med J; 1992 Sep; 105(941):345-7. PubMed ID: 1279493
[TBL] [Abstract][Full Text] [Related]
16. [Model of screening for prostatic cancer among patients with prostate specific antigen concentration of 4-10 ng/ml in blood].
Karazanashvili GG; Managadze LG
Urologiia; 2000; (6):37-41. PubMed ID: 11186321
[TBL] [Abstract][Full Text] [Related]
17. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
18. Free to complexed PSA ratio in differentiating benign prostate hyperplasia from prostate cancer.
Filella X; Alcover J; Corral JM; Molina R; Beardo P; Ballesta AM
Anticancer Res; 2001; 21(5):3717-20. PubMed ID: 11848550
[TBL] [Abstract][Full Text] [Related]
19. [Value of prostate specific antigen in early diagnosis of prostatic cancer].
Xiao LP; Bi XJ; Li YN; Chen XQ; Zhang XF; Yu XP; Liu G; Yang MC; Song Z
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jan; 27(1):107-8, 112. PubMed ID: 17259162
[TBL] [Abstract][Full Text] [Related]
20. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP
Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
